This book presents reflections and research that highlight tensions in the negotiations on pandemic preparedness treaties and revisions to the International Health Regulations, underscoring the geopolitical divide between developed and developing countries. It advocates regional health initiatives as a response to the multilateral impasse and reflects on the erosion of foundational public health concepts such as “essential medicines”.
New pandemics are inevitable. How can we best prepare for them and, above all, how can we avoid the mistakes and injustices made during the COVID-19 pandemic?
How can equitable access to medicines and diagnostics be guaranteed when they are produced in a small number of countries? How can we explain the fact that current funding for cooperation in the field of health is in the hands of a small group of Northern countries and foundations from the North? How can the role of the World Health Organization be strengthened? WHO now plays only a minor role in coordinating public health policies. How is it that the concept of “essential medicines”, a major advance in public health policy, is being replaced by that of “medical countermeasures”, a term more in line with the private sectors?
Preparing for future pandemics forces us to ask ourselves: how can we safeguard the general interest, the defense of human rights and public health?
Negotiating Global Health Policies: Tensions and Dilemmas is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO), the World Trade Organization (WTO), and the World Intellectual Property Organization (WIPO) who participate in international negotiations on health and development. Academics and students of medicine, health sciences, law, sociology and political science, as well as intergovernmental organizations and non-governmental organizations who work on access to medicines and global health issues, also would find the book of interest.
Author: Germán Velásquez is Special Adviser, Policy and Health of the South Centre in Geneva, Switzerland. Previously, he was Director of the Secretariat on Public Health, Innovation and Intellectual Property at WHO. He represented WHO at the WTO TRIPS Council from 2001 to 2010. He is the author and co-author of numerous publications on health economics and medicines, health insurance schemes, globalization, international trade agreements, intellectual property and access to medicines.
He obtained a Master’s degree in Economics and a PhD in Health Economics from Sorbonne University, Paris. In 2010, he received a Honoris Causa PhD on Public Health from the University of Caldas, Colombia and in 2015 he received another Honoris Causa PhD from the Faculty of Medicine of the Complutense University of Madrid, Spain.
The Importance of Balanced Intellectual Property Systems for Patients’ Access to Medicines: An Analysis
By Archana Jatkar and Nicolás Tascón
Access to safe, effective, cost-effective, and quality-assured medicines is fundamental from a patients’ perspective. The International Generic and Biosimilar Medicines Association (IGBA) recently released a reporthighlighting the critical balance between innovation, competition, and timely access to medicines. This article delves into the key findings of IGBA’s report, their implications on patient access to medicines and national healthcare budgets, and the IGBA’s recommendations for improving the global pharmaceutical landscape.
Policy in Practice: Implementing Antimicrobial Stewardship Post-COVID-19
Q&A and Commentary
By Dr Rasha Abdelsalam Elshenawy
This report summarises the key questions and expert commentary for the South Centre, as well as the South Centre Policy Brief on lessons from the COVID-19 pandemic, to strengthen antimicrobial stewardship and provide practical recommendations discussed during the South Centre webinar on “Strengthening Antimicrobial Stewardship: Policy Insights from COVID-19 and Future Pandemic Preparedness.”
Scope of Compulsory License and Government Use of Patented Medicines
To meet public health needs governments can use compulsory licenses and government use as a tool for procurement and import of patented medicines. These mechanisms are provided for in most laws worldwide. The WTO TRIPS Agreement, as reaffirmed by the Doha Declaration on TRIPS and Public Health, recognises the right of WTO members to grant compulsory licenses and their freedom to determine the grounds upon which such licenses may be granted.
This table provides information of instances of their use.
Statement of the Executive Director of the South Centre, Dr. Carlos Correa, at the NAM Health Ministers’ Meeting on the sidelines of the 78th World Health Assembly (May 19-27, 2025)
The decisions to be made at the 78th World Health Assembly will have direct implications not only for national health systems, but also for the very architecture of international cooperation in health. Read the statement by the Executive Director of the South Centre, Dr. Carlos Correa, at the NAM Health Ministers’ Meeting on the sidelines of the 78th WHA.
Leaving the WHO? The US Just Shot Itself in the Foot
By Germán Velásquez
At the start of his second term, United States president Donald Trump has again announced that the US will formally leave the World Health Organization (WHO) in 2025. Leaving the WHO is a financial blow to the Organization, as many have pointed out, but it is much more than that. Trump’s decision to abandon WHO is counterproductive and puts at risk the capacity of the organization to perform its role as the global health agency. The WHO has been central to responding to global health emergencies for more than seven decades. Its work in the fight against diseases such as smallpox, polio, Ebola and HIV/AIDS, or the binding international convention against tobacco use, has saved millions of lives.
The US’ withdrawal from WHO will have a serious impact on various aspects of global health, and the US will itself be directly affected. WHO members should unite to strengthen the WHO and counteract this decision by the current US Administration.
South Centre Statement to the Resumed Thirteenth Meeting of the Intergovernmental Negotiating Body to Draft and Negotiate a WHO Convention, Agreement or Other International Instrument of Pandemic Prevention, Preparedness and Response
7 April 2025
Negotiations resume for a WHO pandemic agreement, aiming to finalise the text in 5 days. Will Member States show the needed leadership and will to deliver an impactful outcome with equity at the core?
Strengthening Antimicrobial Stewardship Policy: Insights from COVID-19 and Future Pandemic Preparedness
South Centre Webinar
Date: 14 April 2025 Time: 12:00 PM – 1:00 PM CEST | 6:00 AM – 7:00 AM EDT | 3:30 PM – 4:30 PM IST Location: Virtual (Zoom)
In this one-hour webinar, we will explore how the COVID-19 pandemic impacted antimicrobial stewardship (AMS) programmes and what lessons can strengthen future pandemic preparedness, especially in low- and middle-income countries (LMICs).
Application de l’Exception Bolar: Différentes approches dans le droit de l’UE
Par Dmytro Doubinsky
Ce Document de recherche aborde le problème toujours plus aigu de l’accès aux médicaments essentiels, en se concentrant sur le rôle des droits de propriété intellectuelle, en particulier les droits de brevet, qui restreignent l’accès en permettant des monopoles sur le marché pharmaceutique qui maintiennent les prix des médicaments à un niveau élevé. Le document explore l’exception Bolar, un mécanisme juridique conçu pour permettre aux fabricants de médicaments génériques de demander l’approbation réglementaire avant l’expiration d’un brevet, empêchant ainsi l’extension de facto des monopoles de brevets. L’étude examine la transformation de l’exception Bolar d’un cas juridique spécifique en un instrument important en matière de droit de la propriété intellectuelle, de droit commercial et de droit pharmaceutique. Elle analyse les principaux cadres juridiques internationaux et les directives européennes relatifs à l’exception Bolar et met en évidence les interprétations divergentes de l’exception dans les jurisprudences allemande et polonaise. Grâce à cette analyse comparative, le document encourage une mise en œuvre plus large des exceptions Bolar afin d’améliorer l’accès à des médicaments abordables et de réduire les coûts des soins de santé.
Submission by the South Centre to the Office of the United Nations High Commissioner for Human Rights on Inputs for the comprehensive report on ensuring access to medicines, vaccines and other health products (HRC resolution 50/13)
January 2025
The South Centre has provided input for the OHCHR report on new developments and challenges in ensuring access to medicines, vaccines and other health products.
Description: